JPRN-UMIN000011568招募中2 期
enalidomide/dexamethasone Salvage Therapy with stepwise Evatuation for Practical Dose Finding Study - L-STEP
Saitama Medical Center,Saitama Medical University0 个研究点目标入组 10 人开始时间: 2013年8月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Patients with a past history of receiving lenalidomide (2)Patients with a past history of allergy to lenalidomide and thalidomide (3) Patients with non-secretary myeloma, solitary myeloma, plasma cell leukemia, or POEMS syndrome (4) HBs antigen,or HCV antibody positive patients (5) HTLV-1 antibody,or HCV antibody positive patients (6) Patients with a history of malignancies (7) Womeb with pregnancy or during lactation (6) be expected to be alive more than 6 months (7) creatinine clearance>=60ml/min (8) without a history of deep vein thrombosis and pulmonary thrombosis (9) patients who are observed RevMate (10) Patients who have given consent to participate in the study of their own free will after having received from the principal investigator or subinvestigator (and the study collaborator) full information about the purpose and procedure of the study using the Informed Consent Form and Patient Information. (8) Patients with uncontrolled dysfunction of liver, kidney, heart, diabetes, hypertension, and infection (9) Patients with serious abalienation (10) Patients with deep vein thrombosis or pulmonary thrombosis (11) Other patients who are in the opinion of the caring investigator, unfit for enrollment in the study
研究者
相似试验
进行中（未招募）
不适用
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failureThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-ATWilhelminen Krebsforschung GmbH50
进行中（未招募）
1 期
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failure - LDThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-SKWilhelminen Krebsforschung GmbH50
进行中（未招募）
1 期
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failureThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-DEWilhelminen Krebsforschung GmbH50
进行中（未招募）
不适用
enalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failure - LDThere are two patient groups to be included into the study:1) Patients with previously unknown MM and acute light chain induced renal failure 2) Patients with previously diagnosed MM, normal or near normal renal function (GFR minimum 60ml/min and serum creatinine =1.2mg/dl) within the previous 6 weeks before onset of acute light chain induced deterioration of renal function to GFR <50ml/min and serum creatinine not less than 2mg/dL.EUCTR2008-006497-15-CZWilhelminen Krebsforschung GmbH50
进行中（未招募）
不适用
SALVAGE TREATMENT WITH LENALIDOMIDE AND DEXAMETHASONE (LEN-DEX) IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL) - NDTreatment of patients with MCL relapsed or refractory to at least one line of chemotherapy, not eligible for or relapsed after more intensive treatments.MedDRA version: 9.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaEUCTR2008-000044-14-ITIIL INTERGRUPPO ITALIANO LINFOMI ONLUS